In vitro and in vivo histone deacetylase inhibitor therapy with vorinostat and paclitaxel in ovarian cancer models: Does timing matter?
Summary of "In vitro and in vivo histone deacetylase inhibitor therapy with vorinostat and paclitaxel in ovarian cancer models: Does timing matter?"
OBJECTIVE:
To determine whether the combination of vorinostat (suberoylanilide hydroxamic acid, SAHA) and paclitaxel is more effective than either individual agent and to evaluate the effect of drug sequencing in ovarian cancer cell lines and in mouse models.
METHODS:
For in vitro studies, three ovarian cancer cell lines (2774, SKOV-3 and OVCAR-3) were grown with either 10nM paclitaxel, or vorinostat (0.3, 1, 3 or 10muM), or vehicle (DMSO) and subsequently treated with 10nM paclitaxel, or vorinostat (0.3, 1, 3, or 10muM), or DMSO. Apoptosis was analyzed. In the mouse, treatments were given for a total of 5 weeks: vehicle control, paclitaxel, vorinostat, vorinostat followed by paclitaxel, paclitaxel followed by vorinostat, and simultaneous vorinostat and paclitaxel. Endpoints were survival, ascites and tumor weight. Protein expression was analyzed by Western blots.
RESULTS:
In two cell lines (SKOV-3, OVCAR-3), the sequence of vorinostat and paclitaxel administration did not significantly alter the apoptosis percentages and the combination was not superior to individual agents. However, in one cell line (2774), the most effective combination in achieving apoptosis was paclitaxel followed by low dose vorinostat. In the mouse model, both control and vorinostat alone treatment groups were inferior to paclitaxel and the combination treatment groups, but no significant differences were observed between the groups receiving both paclitaxel and vorinostat based on the sequence of administration.
CONCLUSIONS:
The efficacy of the combination and sequence of vorinostat and paclitaxel administration was cell line dependent and suggests that responses vary based on tumor specific characteristics.
Affiliation
Division of Gynecologic Oncology, University of Virginia Health System, Charlottesville, VA, USA.
Journal Details
This article was published in the following journal.
Name: Gynecologic oncology
ISSN: 1095-6859
Pages:
Links
- PubMed Source: http://www.ncbi.nlm.nih.gov/pubmed/20673975
- DOI: http://dx.doi.org/10.1016/j.ygyno.2010.06.030
Medical and Biotech [MESH] Definitions
Histone Deacetylase 1
A histone deacetylase subtype that is found along with HISTONE DEACETYLASE 2; RETINOBLASTOMA-BINDING PROTEIN 4; and RETINOBLASTOMA-BINDING PROTEIN 7 as core components of histone deacetylase complexes.
Histone Deacetylase 2
A histone deacetylase subtype that is found along with HISTONE DEACETYLASE 1; RETINOBLASTOMA-BINDING PROTEIN 4; and RETINOBLASTOMA-BINDING PROTEIN 7 as core components of histone deacetylase complexes.
Sin3 Histone Deacetylase And Corepressor Complex
A multisubunit enzyme complex that regulates GENETIC TRANSCRIPTION by deacetylating the HISTONE residues of NUCLEOSOMES.
Histone Deacetylase Inhibitors
Compounds that inhibit HISTONE DEACETYLASES. This class of drugs may influence gene expression by increasing the level of acetylated HISTONES in specific CHROMATIN domains.
Mi-2 Nucleosome Remodeling And Deacetylase Complex
A enzyme complex involved in the remodeling of NUCLEOSOMES. The complex is comprised of at least seven subunits and includes both histone deacetylase and ATPase activities.
PubMed Articles
In preclinical models, the histone deacetylase inhibitor vorinostat sensitizes breast cancer cells to tubulin-polymerizing agents and to anti-vascular endothelial growth factor-directed therapies. We...
Histone deacetylase (HDAC) inhibitors can radiosensitize cancer cells. Radiation is critical in high-risk neuroblastoma treatment, and combinations of HDAC inhibitor vorinostat and radiation are propo...
Vorinostat is a histone deacetylase inhibitor that effectively suppresses cancer-cell proliferation by inducing cell-cycle arrest and/or apoptosis. We now show the involvement of p38 mitogen-activated...
We synthesized a novel hydroxamate-based pan-histone deacetylase inhibitor (HDACI), CG200745 {(E)-2-(Naphthalen-1-yloxymethyl)-oct-2-enedioic acid 1-[(3-dimethylamino-propyl)-amide] 8-hydroxyamide]}....
Glucocorticoids play a critical role in the therapy of lymphoid malignancies, including pediatric acute lymphoblastic leukemia (ALL), although mechanisms underlying cellular resistance remain unclear....
Clinical Trials
There is scientific rationale for exploring the role of vorinostat, histone deacetylase inhibitor with capecitabine (X) and cisplatin (P), one of standard chemotherapy in patients with adv...
This is an investigational study that increases the dosage to determine the safety/tolerability, and efficacy of a histone deacetylase inhibitor in combination with Targretin in patients w...
The purpose of this research study is to: 1) Determine the highest dose of the drug vorinostat that can be given safely in combination with carboplatin and gemcitabine and 2) determine how...
Hydroxychloroquine + Vorinostat in Advanced Solid Tumors
This study is an open label non randomized study of hydroxychloroquine (HCQ) with histone deacetylase (HDAC) inhibitor Vorinostat in patients with advanced solid tumors to determine the ma...
Vorinostat in Combination With Palliative Radiotherapy for Patients With Non-Small Cell Lung Cancer
This is a dose escalation study that will assess the safety of Vorinostat, a Histone Deacetylase (HDAC) inhibitor, in combination with palliative radiotherapy in patients with advanced or...
